155 related articles for article (PubMed ID: 15205948)
41. Concentration and time dependence of the toxicity of fluorinated pyrimidines to HT 29 colorectal carcinoma cells.
Link KH; Aigner KR; Peschau K; Warthona M; Schwemmle K; Danenberg PV
Cancer Chemother Pharmacol; 1988; 22(1):58-62. PubMed ID: 2969305
[TBL] [Abstract][Full Text] [Related]
42. Targeted delivery of 5-fluorouracil to HT-29 cells using high efficient folic acid-conjugated nanoparticles.
Wang Y; Li P; Chen L; Gao W; Zeng F; Kong LX
Drug Deliv; 2015 Feb; 22(2):191-8. PubMed ID: 24437926
[TBL] [Abstract][Full Text] [Related]
43. Recombinant human interferon alpha-2a increases 5-fluorouracil efficacy by elevating fluorouridine concentration in tumor tissue.
Kase S; Kubota T; Watanabe M; Teramoto T; Kitajima M; Hoffman RM
Anticancer Res; 1994; 14(3A):1155-9. PubMed ID: 8074466
[TBL] [Abstract][Full Text] [Related]
44. Transcription and activity of 5-fluorouracil converting enzymes in fluoropyrimidine resistance in colon cancer in vitro.
Mader RM; Sieder AE; Braun J; Rizovski B; Kalipciyan M; Mueller MW; Jakesz R; Rainer H; Steger GG
Biochem Pharmacol; 1997 Dec; 54(11):1233-42. PubMed ID: 9416974
[TBL] [Abstract][Full Text] [Related]
45. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer.
Kemeny N; Garay CA; Gurtler J; Hochster H; Kennedy P; Benson A; Brandt DS; Polikoff J; Wertheim M; Shumaker G; Hallman D; Burger B; Gupta S
J Clin Oncol; 2004 Dec; 22(23):4753-61. PubMed ID: 15570076
[TBL] [Abstract][Full Text] [Related]
46. Cetuximab in the first-line treatment of K-ras wild-type metastatic colorectal cancer: the choice and schedule of fluoropyrimidine matters.
Ku GY; Haaland BA; de Lima Lopes G
Cancer Chemother Pharmacol; 2012 Aug; 70(2):231-8. PubMed ID: 22699811
[TBL] [Abstract][Full Text] [Related]
47. A phase II study of irinotecan alternated with a weekly schedule of oxaliplatin, high-dose leucovorin and 48-hour infusion 5-fluorouracil in patients with advanced colorectal cancer.
Rosati G; Tucci A; Rinaldi A; Colarusso D; Pizza C; Reggiardo G; Manzione L
Oncology; 2004; 66(5):371-8. PubMed ID: 15331924
[TBL] [Abstract][Full Text] [Related]
48. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study.
Hochster HS; Hart LL; Ramanathan RK; Childs BH; Hainsworth JD; Cohn AL; Wong L; Fehrenbacher L; Abubakr Y; Saif MW; Schwartzberg L; Hedrick E
J Clin Oncol; 2008 Jul; 26(21):3523-9. PubMed ID: 18640933
[TBL] [Abstract][Full Text] [Related]
49. Phase III trial of irinotecan plus infusional 5-fluorouracil/folinic acid versus irinotecan plus oxaliplatin as first-line treatment of advanced colorectal cancer.
Fischer von Weikersthal L; Schalhorn A; Stauch M; Quietzsch D; Maubach PA; Lambertz H; Oruzio D; Schlag R; Weigang-Köhler K; Vehling-Kaiser U; Schulze M; Truckenbrodt J; Goebeler M; Mittermüller J; Bosse D; Szukics B; Grundeis M; Zwingers T; Giessen C; Heinemann V
Eur J Cancer; 2011 Jan; 47(2):206-14. PubMed ID: 20971632
[TBL] [Abstract][Full Text] [Related]
50. Multicenter phase II study of fractionated bimonthly oxaliplatin with leucovorin and 5-fluorouracil in patients with metastatic colorectal cancer, pre-treated with chemotherapy.
Recchia F; Rea S; Nuzzo A; Lalli A; Di Lullo L; De Filippis S; Saggio G; Di Blasio A; Massa E; Mantovani G
Oncol Rep; 2003; 10(1):65-9. PubMed ID: 12469146
[TBL] [Abstract][Full Text] [Related]
51. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.
Hegewisch-Becker S; Graeven U; Lerchenmüller CA; Killing B; Depenbusch R; Steffens CC; Al-Batran SE; Lange T; Dietrich G; Stoehlmacher J; Tannapfel A; Reinacher-Schick A; Quidde J; Trarbach T; Hinke A; Schmoll HJ; Arnold D
Lancet Oncol; 2015 Oct; 16(13):1355-69. PubMed ID: 26361971
[TBL] [Abstract][Full Text] [Related]
52. Inhibitory effect of combined administration with CPT-11 and 5-fluorouracil in vitro and in vivo.
Satoh H; Ohtomo M; Ishikawa H; Kamma H; Ohtsuka M; Hasegawa S
Cancer Biochem Biophys; 1999 Jul; 17(1-2):59-67. PubMed ID: 10738902
[TBL] [Abstract][Full Text] [Related]
53. [The validity of full administration of 5-fluorouracil, irinotecan, and oxaliplatin to unresectable or recurrent colorectal cancer].
Ishibashi K; Okada N; Ishiguro T; Okita T; Mitsuhashi T; Miyazaki T; Yokoyama M; Matsuki M; Sano M; Inoue N; Ishida H
Gan To Kagaku Ryoho; 2008 Nov; 35(12):2289-91. PubMed ID: 19106599
[TBL] [Abstract][Full Text] [Related]
54. Review of the role of CPT-11 in the treatment of colorectal cancer.
Rougier P; Mitry E
Clin Colorectal Cancer; 2001 Aug; 1(2):87-94. PubMed ID: 12445366
[TBL] [Abstract][Full Text] [Related]
55. Improvement of the therapeutic index of anticancer drugs by the superoxide dismutase mimic mangafodipir.
Alexandre J; Nicco C; Chéreau C; Laurent A; Weill B; Goldwasser F; Batteux F
J Natl Cancer Inst; 2006 Feb; 98(4):236-44. PubMed ID: 16478742
[TBL] [Abstract][Full Text] [Related]
56. On the mechanism of cytotoxicity of fluorinated pyrimidines in four human colon adenocarcinoma xenografts maintained in immune-deprived mice.
Houghton JA; Houghton PJ
Cancer; 1980 Mar; 45(5 Suppl):1159-67. PubMed ID: 6444543
[TBL] [Abstract][Full Text] [Related]
57. Oxaliplatin plus irinotecan compared with irinotecan alone as second-line treatment after single-agent fluoropyrimidine therapy for metastatic colorectal carcinoma.
Haller DG; Rothenberg ML; Wong AO; Koralewski PM; Miller WH; Bodoky G; Habboubi N; Garay C; Olivatto LO
J Clin Oncol; 2008 Oct; 26(28):4544-50. PubMed ID: 18824706
[TBL] [Abstract][Full Text] [Related]
58. A phase I, dose-finding study of irinotecan (CPT-11) short i.v. infusion combined with fixed dose of 5-fluorouracil (5-FU) protracted i.v. infusion in adult patients with advanced solid tumours.
Sastre J; Paz-Ares L; Carcas A; Alfonso R; Grávalos C; Frías J; Guerra P; Pronk L; Cortés-Funes H; Díaz-Rubio E
Cancer Chemother Pharmacol; 2005 May; 55(5):453-60. PubMed ID: 15818508
[TBL] [Abstract][Full Text] [Related]
59. [The lethal effect of combined MDR1 antisense RNA with oxaliplatin and 5-FU on drug-resistant rectal carcinoma cells].
Chen G; Li SY; Yu B; An P; Cai HY
Zhonghua Wai Ke Za Zhi; 2006 Jun; 44(11):770-3. PubMed ID: 16836929
[TBL] [Abstract][Full Text] [Related]
60. Sequence-dependent enhancement of HCT-8 cell kill by trimetrexate and fluoropyrimidines: implications for the mechanism of this interaction.
Sobrero A; Romanini A; Russello O; Nicolin A; Rosso R; Bertino JR
Eur J Cancer Clin Oncol; 1989 Jun; 25(6):977-82. PubMed ID: 2526736
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
